Hinge Health’s long-anticipated IPO is generating significant buzz as the first major digital health offering since Waystar’s debut in 2024, raising questions about whether the public markets will value Hinge at or near its prior $6.2 billion private valuation. While the company has shown impressive revenue growth to $390.4M in 2024 and improved margins, concerns remain about future growth beyond the saturated self-insured employer market and its ability to expand beyond musculoskeletal (MSK) care into adjacent areas like behavioral health or GI. As a leader in digital MSK, Hinge faces pressure to either build or buy capabilities in new clinical categories to meet employers’ growing demand for consolidated solutions.
Trending
- AI-Assisted Colonoscopy and the Diminutive Adenoma Dilemma (Los Angeles Times)
- BE Surveillance, Outpatient ESD, and More (GI & Endoscopy News)
- HHS-OIG Issues Favorable Advisory Opinion for Free Multi-Cancer Detection Supplemental Reports Provided with Medicare-Covered Colorectal Cancer Screening Tests (The National Law Review)
- Physician–researcher’s work yields landmark five-year data for Crohn’s disease drug (Medical Xpress)
- CU Anschutz Biobank Partners with Tech Company to Advance Gut Research and Patient Care (The Regents of the University of Colorado)
- Novant Health adds leading gastroenterology clinicians to its Lowcountry network (Novant Health)
- Solutions Emerging for Post-GLP-1 Weight Regain (Medscape)
- CMS Grants Medicare Coverage for ColoSense®, Expanding Access to Simplified Noninvasive Colorectal Cancer Screening (Business Wire)
